SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Doc Bones8/26/2008 2:41:12 AM
   of 7143
 
Depression Treatment Cymbalta
Effective as Pain Reliever, Lilly Says

By AJA CARMICHAEL
August 25, 2008 12:25 p.m.

Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug "significantly" reduced chronic lower-back pain.

Lilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.

According to results of a 236-patient study released at the annual congress of the European Federation of Neurological Societies in Madrid, 31% of patients taking Cymbalata reported a 50% reduction in pain, versus 19% of patients taking placebo. Patients experienced significant relief in pain the first week and continued throughout the 13-week acute-therapy phase.

"Chronic low back pain can have a significant impact on a person's ability to do the things they enjoy," said Vladimir Skljarevski, lead study author at Lilly Research Laboratories. "This research may offer hope to those dealing with this debilitating condition."

Indianapolis-based Lilly filed an application in May with the Food and Drug Administration to allow Cymbalta be prescribed for managing chronic pain.

online.wsj.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News